BioWorld - Friday, December 26, 2025
To read the full story, subscribe or sign in.
Cancer
Chengdu Chipscreen Pharmaceutical describes new WRN inhibitors
Dec. 2, 2025
Chengdu Chipscreen Pharmaceutical Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
BioWorld ScienceCancerPatents